TransMedics Group (NASDAQ:TMDX) Stock Price Down 5.9% – Here’s What Happened

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price was down 5.9% on Monday . The stock traded as low as $71.20 and last traded at $71.80. Approximately 621,149 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 2,119,450 shares. The stock had previously closed at $76.32.

Analyst Upgrades and Downgrades

TMDX has been the topic of several research reports. Canaccord Genuity Group reduced their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. TD Cowen lowered their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Robert W. Baird reduced their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Performance

The firm has a market cap of $2.33 billion, a price-to-earnings ratio of 73.76 and a beta of 2.12. The stock’s fifty day moving average is $67.81 and its two-hundred day moving average is $100.76. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Institutional Investors Weigh In On TransMedics Group

Hedge funds have recently made changes to their positions in the business. Braidwell LP acquired a new stake in TransMedics Group in the 4th quarter valued at approximately $57,493,000. Norges Bank bought a new stake in shares of TransMedics Group during the fourth quarter valued at about $22,861,000. Mackenzie Financial Corp lifted its holdings in TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after purchasing an additional 349,403 shares during the period. Dimensional Fund Advisors LP grew its position in TransMedics Group by 1,565.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock valued at $16,820,000 after buying an additional 253,624 shares in the last quarter. Finally, Emerald Advisers LLC grew its position in TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after buying an additional 220,804 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.